Ceratgen

Ceratgen, founded in 2020 with headquarters in Seoul, South Korea, develops regenerative therapeutics to treat diseases by replacing human tissues and organs. The company is led by co-CEOs Sang Gil Lee and Seung Woo Cho. Ceratgen aims to deliver personalized regenerative medicine by integrating advanced organoid technologies with proprietary biomaterials.

The company's core technology focuses on creating "bio-organs" that are structurally and functionally similar to real organs. This is achieved through three main pillars: organoid culture and manufacturing, organoid advancement, and advanced engraftment technology. A key innovation is a decellularized, organ-specific matrix that provides an optimal microenvironment for organoid growth, maturation, and function. This is combined with a bio-adhesive hydrogel, developed using biomimetic technology, which ensures the safe and extended lifespan of transplanted bioengineered organs.

Ceratgen operates a dual business model. It develops its own pipeline of regenerative medicines targeting conditions like nonalcoholic steatohepatitis (NASH), Alzheimer's disease, and pulmonary fibrosis. Concurrently, it offers an organoid-based drug evaluation service for the pharmaceutical industry. This service provides a more accurate and ethically responsible alternative to animal testing, using human-derived cell models to screen drug candidates and assess efficacy and side effects before clinical trials. The company has received funding through an accelerator program and seed/early-stage venture capital rounds.

Keywords: regenerative therapeutics, organoid technology, biomaterials, bio-organs, tissue engineering, drug discovery, cell therapy, drug evaluation platform, decellularized matrix, functional hydrogel, personalized medicine, nonalcoholic steatohepatitis, Alzheimer's disease, pulmonary fibrosis, animal testing alternatives, bio-mimicry, engraftment technology, stem cells, preclinical screening